Use of an artificial beta cell in surgery

Area of Science:

• Endocrinology
• Surgical Medicine
• Metabolic Regulation

Background:

• Surgical procedures can significantly impact glucose metabolism.
• Understanding perioperative glycemic control is crucial for patient outcomes.
• Endogenous insulin suppression during surgery contributes to hyperglycemia.

Purpose of the Study:

• To investigate blood glucose trends in non-diabetic and diabetic patients during surgery.
• To evaluate the efficacy of the Biostator glucose-controlled insulin infusion system for perioperative glycemic management.
• To determine the relationship between exogenous glucose infusion rates and hyperglycemia.

Main Methods:

• Utilized the Biostator glucose-controlled insulin infusion system for real-time blood glucose monitoring.
• Measured serum C-peptide levels to assess endogenous insulin secretion.
• Administered saline or glucose/insulin infusions as per study protocol.
• Monitored glycemic responses in both diabetic and non-diabetic patient cohorts.

Main Results:

• Both non-diabetic and diabetic patients exhibited a tendency towards hyperglycemia during surgery.
• Suppressed endogenous insulin secretion, indicated by C-peptide levels, correlated with hyperglycemia.
• Hyperglycemia severity was linked to the rate of exogenous glucose infusion.
• The Biostator system demonstrated potential for safe and effective blood glucose control in diabetic patients.

Conclusions:

• Perioperative hyperglycemia is a common issue, linked to reduced endogenous insulin secretion.
• The Biostator system shows promise as a tool for managing blood glucose levels in diabetic patients undergoing surgery.
• Careful control of exogenous glucose administration is necessary to mitigate hyperglycemia during surgical interventions.